What is Becton Dickinson?

What is Becton Dickinson?

Becton Dickinson is a public medical technology and life sciences tools company headquartered in Franklin Lakes, NJ. BD reported fiscal 2025 revenue of $21.8 billion, up 8.2% as reported, before the planned Biosciences and Diagnostic Solutions combination with Waters.

Becton Dickinson operates in medical technology and life sciences tools with a portfolio that includes Medication delivery, Medication management solutions, Syringes and needles, Specimen management. BD reported fiscal 2025 revenue of $21.8 billion, up 8.2% as reported, before the planned Biosciences and Diagnostic Solutions combination with Waters. The company employs about 70,000+ and trades as NYSE: BDX, so its buying motion looks like a regulated enterprise account rather than a startup account.

Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Becton Dickinson through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.

For sellers, Becton Dickinson is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.

Sources:Becton Dickinson 2025 resultsBecton Dickinson annual reports

What does Becton Dickinson offer?

Becton Dickinson offers products and services across Medication delivery, Medication management solutions, Syringes and needles, Specimen management and related healthcare workflows.

Sources:Becton Dickinson websiteBecton Dickinson annual reports

How does Becton Dickinson make money?

Becton Dickinson earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.

Becton Dickinson earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $21.8B FY2025 of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.

Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.

Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Becton Dickinson improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.

Sources:Becton Dickinson 2025 resultsBecton Dickinson annual reports

Who leads Becton Dickinson?

Becton Dickinson is led by Tom Polen, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.

Sources:Becton Dickinson leadershipBecton Dickinson annual reports

How do you contact Becton Dickinson's leadership?

Becton Dickinson publishes official BD investor-relations contact route, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.

• Tom PolenChairman, Chief Executive Officer and Presidentofficial BD investor-relations contact route
• Christopher DelOreficeExecutive Vice President and Chief Financial Officerofficial BD investor-relations contact route
• Rick ByrdExecutive Vice President and President, Medication Management Solutionsofficial BD investor-relations contact route

Sources:Becton Dickinson contactBecton Dickinson leadership

How much funding has Becton Dickinson raised?

Becton Dickinson is a mature public company, not a venture-backed startup. It trades as NYSE: BDX and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.

Becton Dickinson's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.

As of June 2026, the current capital lens is NYSE: BDX, $21.8B FY2025 of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.

Seller signal: Becton Dickinson has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.

Sources:Becton Dickinson 2025 resultsNYSE: BDX market data

How did Becton Dickinson get here?

Becton Dickinson grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.

Sources:Becton Dickinson annual reportsBecton Dickinson 2025 results

Who are Becton Dickinson's competitors?

Becton Dickinson competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.

Sources:Becton Dickinson annual reportsBecton Dickinson website